Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7100-7107

  Noguchi, Takuya ^a   Tanimoto, Keiji ^a   Shimokuni, Tatsushi ^a   Ukon, Kei ^a   Tsujimoto, Hiroaki ^b   Fukushima, Masakazu ^b   Noguchi, Tsuyoshi ^c   Kawahara, Katsunobu ^c   Hiyama, Keiko ^a   Nishiyama, Masahiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA;

ARTICLE; CANCER CELL; CELL STRAIN HEPG2; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DPYD GENE; DRUG DEGRADATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME MECHANISM; GENE ACTIVITY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; TIME; TRANSCRIPTION INITIATION;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CARCINOMA, SQUAMOUS CELL; COLONIC NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA METHYLATION; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MOUTH NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 6044238251     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0337     Document Type: Article

References (19)

1. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-6.
2. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30:1517-22.
3. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Basel) 1998; 12(Suppl 7):23-7.
4. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999;5:2672-3.
5. Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5:2006-11.
6. Yokota H, Fernandez-Salguero P, Furuya H, et al. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994;269:23192-6.
7. van Kuilenburg ABP, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.
8. Collie-Duguid ESR, Johnston SJ, Powrie RH, et al. Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun 2000;271:28-35.
9. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002;306:63-73.
10. Collie-Duguid ESR, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000;10:217-23.
11. Shestopal SA, Johnson MR, Diasio RB. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochem Biophys Acta 2000;1494:162-9.
12. Yoshida T, Eguchi H, Nakachi K, et al. Distinct mechanisms of loss of estrogen receptor α gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factor. Carcinogenesis (Lond) 2000;21:2193-201.
13. Müller C, Readhead C, Diederichs S, et al. Methylation of the cyclin Al promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol 2000;20:3316-29.
14. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res 1980;8:4777-90.
15. Shteper PJ, Zcharia E, Ashhab Y, et al. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 2003;22:7737-49.
16. Bird AP. CpG-rich islands and the function of DNA methylation. Nature (Lond) 1986;321:209-13.
17. Chan MWY, Chan LW, Tang NLS, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70.
18. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73.
19. Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002;3:75-82.